Lucid Diagnostics (LUCD) Competitors

$1.09 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.09 0.00 (0.00%)

As of 06:24 PM Eastern

LUCD vs. DRTS, BWAY, NPCE, SIBN, and TCMD

Should you be buying Lucid Diagnostics stock or one of its competitors? The main competitors of Lucid Diagnostics include Alpha Tau Medical (DRTS), Brainsway (BWAY), NeuroPace (NPCE), SiBone (SIBN), and Tactile Systems Technology (TCMD). These companies are all part of the "medical equipment" industry.

How does Lucid Diagnostics compare to Alpha Tau Medical?

Lucid Diagnostics (NASDAQ:LUCD) and Alpha Tau Medical (NASDAQ:DRTS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

: 74.0% of Lucid Diagnostics shares are owned by institutional investors. Comparatively, 2.7% of Alpha Tau Medical shares are owned by institutional investors. 6.8% of Lucid Diagnostics shares are owned by insiders. Comparatively, 39.5% of Alpha Tau Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
: Lucid Diagnostics currently has a consensus target price of $4.13, indicating a potential upside of 278.44%. Alpha Tau Medical has a consensus target price of $8.67, indicating a potential upside of 17.28%. Given Lucid Diagnostics' stronger consensus rating and higher possible upside, analysts plainly believe Lucid Diagnostics is more favorable than Alpha Tau Medical.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lucid Diagnostics
1 Sell rating(s)
0 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.60
Alpha Tau Medical
1 Sell rating(s)

2 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.20
: Lucid Diagnostics has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500. Comparatively, Alpha Tau Medical has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500.
: In the previous week, Alpha Tau Medical had 7 more articles in the media than Lucid Diagnostics. MarketBeat recorded 9 mentions for Alpha Tau Medical and 2 mentions for Lucid Diagnostics. Alpha Tau Medical's average media sentiment score of 0.38 beat Lucid Diagnostics' score of 0.00 indicating that Alpha Tau Medical is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lucid Diagnostics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Alpha Tau Medical
2 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
: Alpha Tau Medical has lower revenue, but higher earnings than Lucid Diagnostics. Alpha Tau Medical is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Lucid Diagnostics $4.71M 45.19 -$58.01M -$0.96 N/A
Alpha Tau Medical N/A N/A -$42.63M -$0.53 N/A
: Alpha Tau Medical has a net margin of 0.00% compared to Lucid Diagnostics' net margin of -1,426.27%. Lucid Diagnostics' return on equity of 0.00% beat Alpha Tau Medical's return on equity.
Company Net Margins Return on Equity Return on Assets
Lucid Diagnostics -1,426.27% N/A -95.51%
Alpha Tau Medical N/A -57.29% -42.39%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Alpha Tau Medical	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lucid Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alpha Tau Medical	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lucid Diagnostics	$4.71M	45.19	-$58.01M	-$0.96	N/A
Alpha Tau Medical	N/A	N/A	-$42.63M	-$0.53	N/A

Company	Net Margins	Return on Equity	Return on Assets
Lucid Diagnostics	-1,426.27%	N/A	-95.51%
Alpha Tau Medical	N/A	-57.29%	-42.39%

Summary

Alpha Tau Medical beats Lucid Diagnostics on 8 of the 15 factors compared between the two stocks.

How does Lucid Diagnostics compare to Brainsway?

Lucid Diagnostics (NASDAQ:LUCD) and Brainsway (NASDAQ:BWAY) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

: Lucid Diagnostics currently has a consensus target price of $4.13, indicating a potential upside of 278.44%. Brainsway has a consensus target price of $15.00, indicating a potential downside of 8.65%. Given Lucid Diagnostics' higher possible upside, analysts plainly believe Lucid Diagnostics is more favorable than Brainsway.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lucid Diagnostics
1 Sell rating(s)
0 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.60
Brainsway
0 Sell rating(s)

0 Hold rating(s)

3 Buy rating(s)

1 Strong Buy rating(s)
3.25
: In the previous week, Lucid Diagnostics and Lucid Diagnostics both had 2 articles in the media. Lucid Diagnostics' average media sentiment score of 0.00 equaled Brainsway'saverage media sentiment score.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lucid Diagnostics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Brainsway
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: 74.0% of Lucid Diagnostics shares are owned by institutional investors. Comparatively, 30.1% of Brainsway shares are owned by institutional investors. 6.8% of Lucid Diagnostics shares are owned by insiders. Comparatively, 19.0% of Brainsway shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
: Brainsway has higher revenue and earnings than Lucid Diagnostics. Lucid Diagnostics is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Lucid Diagnostics $4.71M 45.19 -$58.01M -$0.96 N/A
Brainsway $52.22M 12.59 $7.57M $0.25 65.68
: Lucid Diagnostics has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500. Comparatively, Brainsway has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500.
: Brainsway has a net margin of 14.62% compared to Lucid Diagnostics' net margin of -1,426.27%. Brainsway's return on equity of 11.10% beat Lucid Diagnostics' return on equity.
Company Net Margins Return on Equity Return on Assets
Lucid Diagnostics -1,426.27% N/A -95.51%
Brainsway 14.62% 11.10% 6.97%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Brainsway	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lucid Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Brainsway	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lucid Diagnostics	$4.71M	45.19	-$58.01M	-$0.96	N/A
Brainsway	$52.22M	12.59	$7.57M	$0.25	65.68

Company	Net Margins	Return on Equity	Return on Assets
Lucid Diagnostics	-1,426.27%	N/A	-95.51%
Brainsway	14.62%	11.10%	6.97%

Summary

Brainsway beats Lucid Diagnostics on 11 of the 15 factors compared between the two stocks.

How does Lucid Diagnostics compare to NeuroPace?

NeuroPace (NASDAQ:NPCE) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment.

: In the previous week, NeuroPace had 1 more articles in the media than Lucid Diagnostics. MarketBeat recorded 3 mentions for NeuroPace and 2 mentions for Lucid Diagnostics. NeuroPace's average media sentiment score of 0.00 equaled Lucid Diagnostics'average media sentiment score.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
NeuroPace
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Lucid Diagnostics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: NeuroPace presently has a consensus target price of $18.67, indicating a potential upside of 9.55%. Lucid Diagnostics has a consensus target price of $4.13, indicating a potential upside of 278.44%. Given Lucid Diagnostics' higher possible upside, analysts clearly believe Lucid Diagnostics is more favorable than NeuroPace.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NeuroPace
1 Sell rating(s)
1 Hold rating(s)

4 Buy rating(s)

2 Strong Buy rating(s)
2.88
Lucid Diagnostics
1 Sell rating(s)

0 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.60
: NeuroPace has a beta of 1.92, indicating that its share price is 92% more volatile than the S&P 500. Comparatively, Lucid Diagnostics has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500.
: NeuroPace has higher revenue and earnings than Lucid Diagnostics. NeuroPace is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
NeuroPace $99.99M 5.79 -$21.47M -$0.66 N/A
Lucid Diagnostics $4.71M 45.19 -$58.01M -$0.96 N/A
: 78.8% of NeuroPace shares are held by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are held by institutional investors. 20.5% of NeuroPace shares are held by company insiders. Comparatively, 6.8% of Lucid Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
: NeuroPace has a net margin of -21.47% compared to Lucid Diagnostics' net margin of -1,426.27%. Lucid Diagnostics' return on equity of 0.00% beat NeuroPace's return on equity.
Company Net Margins Return on Equity Return on Assets
NeuroPace -21.47% -105.67% -20.01%
Lucid Diagnostics -1,426.27% N/A -95.51%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroPace	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lucid Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroPace	$99.99M	5.79	-$21.47M	-$0.66	N/A
Lucid Diagnostics	$4.71M	45.19	-$58.01M	-$0.96	N/A

Company	Net Margins	Return on Equity	Return on Assets
NeuroPace	-21.47%	-105.67%	-20.01%
Lucid Diagnostics	-1,426.27%	N/A	-95.51%

Summary

NeuroPace beats Lucid Diagnostics on 11 of the 15 factors compared between the two stocks.

How does Lucid Diagnostics compare to SiBone?

SiBone (NASDAQ:SIBN) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation.

: 98.1% of SiBone shares are held by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are held by institutional investors. 3.9% of SiBone shares are held by insiders. Comparatively, 6.8% of Lucid Diagnostics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
: SiBone has a net margin of -9.41% compared to Lucid Diagnostics' net margin of -1,426.27%. Lucid Diagnostics' return on equity of 0.00% beat SiBone's return on equity.
Company Net Margins Return on Equity Return on Assets
SiBone -9.41% -11.01% -8.12%
Lucid Diagnostics -1,426.27% N/A -95.51%
: SiBone has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Comparatively, Lucid Diagnostics has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500.
: In the previous week, SiBone had 5 more articles in the media than Lucid Diagnostics. MarketBeat recorded 7 mentions for SiBone and 2 mentions for Lucid Diagnostics. SiBone's average media sentiment score of 0.66 beat Lucid Diagnostics' score of 0.00 indicating that SiBone is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
SiBone
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Lucid Diagnostics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: SiBone presently has a consensus target price of $24.00, indicating a potential upside of 77.12%. Lucid Diagnostics has a consensus target price of $4.13, indicating a potential upside of 278.44%. Given Lucid Diagnostics' higher possible upside, analysts clearly believe Lucid Diagnostics is more favorable than SiBone.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SiBone
1 Sell rating(s)
0 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
2.71
Lucid Diagnostics
1 Sell rating(s)

0 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.60
: SiBone has higher revenue and earnings than Lucid Diagnostics. SiBone is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
SiBone $200.93M 2.98 -$18.90M -$0.44 N/A
Lucid Diagnostics $4.71M 45.19 -$58.01M -$0.96 N/A

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-9.41%	-11.01%	-8.12%
Lucid Diagnostics	-1,426.27%	N/A	-95.51%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SiBone	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Lucid Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$200.93M	2.98	-$18.90M	-$0.44	N/A
Lucid Diagnostics	$4.71M	45.19	-$58.01M	-$0.96	N/A

Summary

SiBone beats Lucid Diagnostics on 10 of the 16 factors compared between the two stocks.

How does Lucid Diagnostics compare to Tactile Systems Technology?

Lucid Diagnostics (NASDAQ:LUCD) and Tactile Systems Technology (NASDAQ:TCMD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability.

: Lucid Diagnostics currently has a consensus target price of $4.13, indicating a potential upside of 278.44%. Tactile Systems Technology has a consensus target price of $37.80, indicating a potential upside of 57.17%. Given Lucid Diagnostics' higher probable upside, research analysts clearly believe Lucid Diagnostics is more favorable than Tactile Systems Technology.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lucid Diagnostics
1 Sell rating(s)
0 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.60
Tactile Systems Technology
0 Sell rating(s)

3 Hold rating(s)

3 Buy rating(s)

1 Strong Buy rating(s)
2.71
: Lucid Diagnostics has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500. Comparatively, Tactile Systems Technology has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500.
: Tactile Systems Technology has a net margin of 5.91% compared to Lucid Diagnostics' net margin of -1,426.27%. Tactile Systems Technology's return on equity of 9.84% beat Lucid Diagnostics' return on equity.
Company Net Margins Return on Equity Return on Assets
Lucid Diagnostics -1,426.27% N/A -95.51%
Tactile Systems Technology 5.91% 9.84% 7.55%
: 74.0% of Lucid Diagnostics shares are held by institutional investors. Comparatively, 83.4% of Tactile Systems Technology shares are held by institutional investors. 6.8% of Lucid Diagnostics shares are held by insiders. Comparatively, 2.1% of Tactile Systems Technology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
: In the previous week, Tactile Systems Technology had 8 more articles in the media than Lucid Diagnostics. MarketBeat recorded 10 mentions for Tactile Systems Technology and 2 mentions for Lucid Diagnostics. Lucid Diagnostics' average media sentiment score of 0.00 beat Tactile Systems Technology's score of -0.49 indicating that Lucid Diagnostics is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lucid Diagnostics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Tactile Systems Technology
1 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Tactile Systems Technology has higher revenue and earnings than Lucid Diagnostics. Lucid Diagnostics is trading at a lower price-to-earnings ratio than Tactile Systems Technology, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Lucid Diagnostics $4.71M 45.19 -$58.01M -$0.96 N/A
Tactile Systems Technology $329.52M 1.66 $19.09M $0.83 28.98

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Tactile Systems Technology	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71

Company	Net Margins	Return on Equity	Return on Assets
Lucid Diagnostics	-1,426.27%	N/A	-95.51%
Tactile Systems Technology	5.91%	9.84%	7.55%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lucid Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tactile Systems Technology	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lucid Diagnostics	$4.71M	45.19	-$58.01M	-$0.96	N/A
Tactile Systems Technology	$329.52M	1.66	$19.09M	$0.83	28.98

Summary

Tactile Systems Technology beats Lucid Diagnostics on 11 of the 17 factors compared between the two stocks.

Get Lucid Diagnostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LUCD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LUCD vs. The Competition

Export

Metric	Lucid Diagnostics	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$212.83M	$7.06B	$6.25B	$11.77B
Dividend Yield	N/A	1.74%	2.74%	5.26%
P/E Ratio	-1.14	29.56	29.25	27.07
Price / Sales	45.19	55.84	504.68	73.47
Price / Cash	N/A	24.32	43.30	53.90
Price / Book	-3.52	7.29	9.67	6.69
Net Income	-$58.01M	$158.34M	$3.55B	$332.64M
7 Day Performance	4.81%	2.64%	1.70%	2.01%
1 Month Performance	-4.39%	4.99%	5.62%	9.19%
1 Year Performance	-12.80%	-3.14%	34.42%	39.59%

Lucid Diagnostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LUCD Lucid Diagnostics	2.225 of 5 stars	$1.09 flat	$4.13 +278.4%	N/A	$212.83M	$4.71M	N/A	70
DRTS Alpha Tau Medical	2.5495 of 5 stars	$7.30 -7.7%	$8.67 +18.7%	N/A	$670.93M	N/A	N/A	80	News Coverage
BWAY Brainsway	1.5275 of 5 stars	$16.10 -2.4%	$15.00 -6.8%	N/A	$660.54M	$52.22M	64.40	120
NPCE NeuroPace	1.4476 of 5 stars	$16.89 -2.1%	$18.67 +10.5%	N/A	$585.65M	$99.99M	N/A	170	News Coverage Positive News Upcoming Earnings
SIBN SiBone	2.2894 of 5 stars	$12.36 -6.0%	$24.00 +94.2%	N/A	$581.80M	$200.93M	N/A	350	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LUCD) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lucid Diagnostics (LUCD) Competitors

LUCD vs. DRTS, BWAY, NPCE, SIBN, and TCMD

How does Lucid Diagnostics compare to Alpha Tau Medical?

Summary

How does Lucid Diagnostics compare to Brainsway?

Summary

How does Lucid Diagnostics compare to NeuroPace?

Summary

How does Lucid Diagnostics compare to SiBone?

Summary

How does Lucid Diagnostics compare to Tactile Systems Technology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LUCD vs. The Competition

Lucid Diagnostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lucid Diagnostics (LUCD) Competitors

LUCD vs. DRTS, BWAY, NPCE, SIBN, and TCMD

How does Lucid Diagnostics compare to Alpha Tau Medical?

Summary

How does Lucid Diagnostics compare to Brainsway?

Summary

How does Lucid Diagnostics compare to NeuroPace?

Summary

How does Lucid Diagnostics compare to SiBone?

Summary

How does Lucid Diagnostics compare to Tactile Systems Technology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LUCD vs. The Competition

Lucid Diagnostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools